Merck's cancer drug Keytruda is expected to be the top-selling drug globally in 2024, according to data published by Statista.
The data analytics firm EvaluatePharma compiled the forecasts based on pharmaceutical companies' sales projections as of December 2023. Humira, AbbVie's best-selling anti-inflammatory drug, is notably absent from the list, as the drug lost its market exclusivity in 2023.
Here are the 10 projected best-selling drugs in 2024 and their expected global sales:
1. Keytruda (Merck) — $27.2 billion
2. Ozempic (Novo Nordisk) — $16.1 billion
3. Dupixent (Sanofi) — $13.5 billion
4. Eliquis (Bristol Myers Squibb) — $13.3 billion
5. Biktarvy (Gilead) — $12.6 billion
6. Darzalex (Johnson & Johnson) — $12 billion
7. Opdivo (Bristol Myers Squibb/Ono Pharmaceutical) — $11.3 billion
8. Comimaty (Pfizer/BioNTech) — $10.8 billion
9. Gardasil (Merck/CSL) — $10 billion
10. Skyrizi (AbbVie) —$9.9 billion
